Recent CADL News
- Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference • GlobeNewswire Inc. • 06/18/2024 12:00:00 PM
- Candel Therapeutics to Join Russell 3000® Index • GlobeNewswire Inc. • 06/11/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/30/2024 09:20:30 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/30/2024 08:30:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 08:15:12 PM
- FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma • GlobeNewswire Inc. • 05/30/2024 12:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/24/2024 11:30:40 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 09:05:10 PM
- Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting • GlobeNewswire Inc. • 05/23/2024 09:00:00 PM
- Candel Therapeutics to Present at the Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/22/2024 12:00:00 PM
- Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting • GlobeNewswire Inc. • 05/20/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 12:30:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 12:15:12 PM
- Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 05/14/2024 12:00:00 PM
- Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting • GlobeNewswire Inc. • 04/25/2024 12:00:00 PM
- Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer • GlobeNewswire Inc. • 04/11/2024 01:00:00 PM
- Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors • GlobeNewswire Inc. • 04/09/2024 12:00:00 PM
- Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer • GlobeNewswire Inc. • 04/04/2024 12:00:00 PM
- Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma • GlobeNewswire Inc. • 03/28/2024 08:05:00 PM
- Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 03/28/2024 12:05:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 01:00:10 PM
- Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate • GlobeNewswire Inc. • 03/05/2024 09:30:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/13/2024 02:00:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 12:45:10 PM
- CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma • GlobeNewswire Inc. • 02/13/2024 12:30:00 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM